<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02496364</url>
  </required_header>
  <id_info>
    <org_study_id>ATX-2015</org_study_id>
    <nct_id>NCT02496364</nct_id>
  </id_info>
  <brief_title>Evaluation of Topical and Intravenous Tranexamic Acid in Surgical Treatment of Lumbar Degenerative Disease</brief_title>
  <official_title>Topical and Intravenous Use of Tranexamic Acid in Posterior Lumbar Interbody Fusion - A Prospective, Double-blind, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Traumatologia e Ortopedia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Traumatologia e Ortopedia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lumbar degenerative disease surgery entails in a high blood loss, requiring often for blood
      transfusion. The cost and risks involved in the use of allogeneic blood have motivated
      research methods to reduce operative bleeding in these patients. One such method is the use
      of anti-fibrinolytic drugs, among which is tranexamic acid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll 144 middle-aged and aged patients undergoing Posterior Lumbar
      Interbody Fusion (PLIF) with the diagnosis of Lumbar Degenerative Disease. The primary aim is
      to determine if topical application of tranexamic acid is more effective than intravenous
      infusion at decreasing blood loss and blood transfusion perioperatively in middle-aged and
      aged patients presenting for PLIF surgery.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood loss measurement</measure>
    <time_frame>27 hours</time_frame>
    <description>Intraoperative blood loss (3 hours) plus 24 hours postoperative blood loss will be measured in ml/kg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion necessity</measure>
    <time_frame>27 hours</time_frame>
    <description>Hemoglobin level less than 8g/dl, hematocrit less than 24% or others symptoms suggesting hypovolemia will be indicatives for blood transfusion intraoperative and postoperative.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Other Fusion of Spine, Lumbar Region</condition>
  <condition>Scoliosis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergoing PLIF will be randomized for Intravenous and topical application of tranexamic acid.
Tranexamic acid diluted in saline solution 0,9% to reach a concentration of 5mg/ml for Intravenous infusion;
Tranexamic acid diluted in saline solution 0,9% to reach a concentration of 30mg/ml topical application.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients undergoing PLIF will be randomized for Intravenous infusion of tranexamic acid and topical application of placebo (i.e. saline solution 0,9%)
Tranexamic acid diluted in saline solution 0,9% to reach a concentration of 5mg/ml for Intravenous infusion;
Placebo for topical application, up to 100ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients undergoing PLIF will be randomized for topical application of tranexamic acid and intravenous infusion of placebo (i.e. saline solution 0,9%)
Tranexamic acid diluted in saline solution 0,9 to reach a concentration of 30mg/ml for topical application;
Placebo for intravenous infusion, up to 500ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients undergoing PLIF will be randomized for Intravenous and topical application of placebo (i.e. saline solution 0,9%).
Placebo for intravenous infusion, up to 500ml;
Placebo for topical application, up to 100ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Topical)</intervention_name>
    <description>Saline Solution 0,9% in situ, up to 100ml;</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <other_name>Saline Solution 0,9%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Intravenous)</intervention_name>
    <description>Saline Solution 0,9% in the vein, up to 500ml: 200ml as loading dose over 15 minutes followed by 1ml/Kg/hr throughout the surgery, in a maximum volume of 300ml</description>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <other_name>Saline Solution 0,9%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid (Topical)</intervention_name>
    <description>30mg/ml of tranexamic acid in situ during surgery, up to 100ml</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <other_name>Transamin, TXA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid (Intravenous)</intervention_name>
    <description>5mg/ml of tranexamic acid in the vein, up to 500ml: 200ml (5mg/ml) as loading dose over 15 minutes followed by 1ml/Kg/hr (5mg/ml) throughout the surgery, in a maximum volume of 300ml.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Transamin, TXA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of lumbar degenerative disease with segmental instability and/or lumbar
             stenosis;

          -  Having a body weight less than 100kg

          -  Indicative of Posterior lumbar interbody fusion in three levels or less

        Exclusion Criteria:

          -  Diagnosis of renal and hepatic insufficiency

          -  History of bleeding disorders and thromboembolism

          -  History coronary heart disease

          -  History peripheral vascular disease

          -  Commonly used anticoagulant drug

          -  Contraindication to the use of tranexamic acid

          -  Surgery history in the spine

          -  Religious restrictions on blood transfusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vinicius M da Rocha, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Traumatology and Orthopedics</affiliation>
  </overall_official>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2015</study_first_submitted>
  <study_first_submitted_qc>July 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <last_update_submitted>May 9, 2016</last_update_submitted>
  <last_update_submitted_qc>May 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Traumatologia e Ortopedia</investigator_affiliation>
    <investigator_full_name>Vinicius Magno da Rocha</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Tranexamic Acid</keyword>
  <keyword>Scoliosis</keyword>
  <keyword>bleeding control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scoliosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

